Company Presentation

Aukera Therapeutics is a spin-off from the Biozentrum of the University of Basel. Aukera Therapeutics builds a discovery engine that allows designing new classes of drugs to selectively target different branches of the mTOR pathway. The lead program selectively targets mTOR complex 1 for the treatment of rare diseases, cancer, and neurodegenerative diseases where Aukera Therapeutics’ approach uniquely addresses unmet medical needs.